clinical trial · NCT03811561
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
Novo Nordisk A/S·phase3·active not recruiting·n = 1,500
Diabetes Mellitus, Type 2SemaglutidePlacebo (semaglutide)
brief summary
This study will look at the long-term effects of semaglutide (active medicine) on diabetic eye disease when compared to placebo (dummy medicine). The study will be performed in people with type 2 diabetes. Participants will either get semaglutide or placebo in addition to their diabetes medicines - which treatment the participant gets is decided by chance. Participants will inject the study medicine using a pen-injector. The medicine must be injected in a skin fold in the stomach, thigh or upper arm once a week. The study will last for 5 years.
started
May 8, 2019
primary completion
Nov 7, 2027
completion
Nov 7, 2027
last updated
Aug 4, 2026
official title
Long-term Effects of Semaglutide on Diabetic Retinopathy in Subjects With Type 2 Diabetes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol